Nod for new self-developed cancer drug
Print Edition
China has granted market access to a self-developed cancer drug, the National Medical Products Administration announced.
The drug, known as Brukinsa (zanubrutinib) in capsule form, was developed by the biotechnology company BeiGene.
It is for the treatment of adult patients with mantle cell lymphoma, who have received at least one prior therapy, and also for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The drug was approved through a priority review procedure and its marketing authorization holder should continue with the confirmatory clinical trials, according to the administration.
The approval of the drug will provide an important treatment option for Chinese patients with lymphoma.
Wu Xiaobin, president of BeiGene, said that the development of the drug has taken more than eight years and around 25 clinical trials have been carried out in more than 20 countries, involving in excess of 500 international clinical experts.
More than 1,700 patients have joined the clinical trials globally.
The approval of the drug also underlines China鈥檚 progress in developing innovative drugs, Wu noted.
In November last year, the drug received approval from the United States Food and Drug Administration as a treatment for MCL in adult patients who have received at least one prior therapy.
Wang Zhiwei, vice president of BeiGene, said the company鈥檚 production line in Suzhou, east China鈥檚 Jiangsu Province, has an annual output of 100 million capsules, which can ensure the demand of the domestic market as well as the international market.
Lymphoma is a type of blood cancer which has seen increasing incidence both in China and the world.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
